trial

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia

NCTId NCT01556763
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 21 (actual)
Sponsored by FORUM Pharmaceuticals Inc
Primary completion 2008-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
21 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2008-04
Primary completion
2008-08
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
EVP-6124 (0.3 mg/day)EVP-6124 (1.0 mg/day)Antipsychotic therapy

Sponsors

FORUM Pharmaceuticals IncLead Sponsor

Investigators

1
Sheldon H. Preskorn, M.D.Principal Investigator

Sites

1 total
Wichita, United States

Facts & assertions

4 sourced
Enrollment
21
Phase
PHASE1
Primary Completion Date
2008-08
Status
COMPLETED
relationships
The graph out of here
drug
EVP-6124 (0.3 mg/day)
drug
EVP-6124 (1.0 mg/day)
drug
Antipsychotic therapy
drug
lead_sponsor
FORUM Pharmaceuticals Inc
company
indication
Central Nervous System Diseases
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
investigator
Sheldon H. Preskorn, M.D.
person